Literature DB >> 16437557

Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2.

Stephan Züchner1, Peter De Jonghe, Albena Jordanova, Kristl G Claeys, Velina Guergueltcheva, Sylvia Cherninkova, Steven R Hamilton, Greg Van Stavern, Karen M Krajewski, Jeffery Stajich, Ivajlo Tournev, Kristien Verhoeven, Christine T Langerhorst, Marianne de Visser, Frank Baas, Thomas Bird, Vincent Timmerman, Michael Shy, Jeffery M Vance.   

Abstract

OBJECTIVE: Charcot-Marie-Tooth (CMT) neuropathy with visual impairment due to optic atrophy has been designated as hereditary motor and sensory neuropathy type VI (HMSN VI). Reports of affected families have indicated autosomal dominant and recessive forms, but the genetic cause of this disease has remained elusive.
METHODS: Here, we describe six HMSN VI families with a subacute onset of optic atrophy and subsequent slow recovery of visual acuity in 60% of the patients. Detailed clinical and genetic studies were performed.
RESULTS: In each pedigree, we identified a unique mutation in the gene mitofusin 2 (MFN2). In three families, the MFN2 mutation occurred de novo; in two families the mutation was subsequently transmitted from father to son indicating autosomal dominant inheritance.
INTERPRETATION: MFN2 is a mitochondrial membrane protein that was recently reported to cause axonal CMT type 2A. It is intriguing that MFN2 shows functional overlap with optic atrophy 1 (OPA1), the protein underlying the most common form of autosomal dominant optic atrophy, and mitochondrial encoded oxidative phosphorylation components as seen in Leber's hereditary optic atrophy. We conclude that autosomal dominant HMSN VI is caused by mutations in MFN2, emphasizing the important role of mitochondrial function for both optic atrophies and peripheral neuropathies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16437557     DOI: 10.1002/ana.20797

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  105 in total

Review 1.  Role of mitofusin 2 in cardiovascular oxidative injury.

Authors:  Ming Zheng; Rui-Ping Xiao
Journal:  J Mol Med (Berl)       Date:  2010-09-08       Impact factor: 4.599

Review 2.  Dominant optic atrophy.

Authors:  Guy Lenaers; Christian Hamel; Cécile Delettre; Patrizia Amati-Bonneau; Vincent Procaccio; Dominique Bonneau; Pascal Reynier; Dan Milea
Journal:  Orphanet J Rare Dis       Date:  2012-07-09       Impact factor: 4.123

Review 3.  Inherited neuropathies: clinical overview and update.

Authors:  Christopher J Klein; Xiaohui Duan; Michael E Shy
Journal:  Muscle Nerve       Date:  2013-06-26       Impact factor: 3.217

4.  A novel de novo MFN2 mutation causing CMT2A with upper motor neuron signs.

Authors:  S Ajroud-Driss; F Fecto; K Ajroud; Y Yang; S Donkervoort; N Siddique; T Siddique
Journal:  Neurogenetics       Date:  2009-04-07       Impact factor: 2.660

Review 5.  Mitochondrial protein quality control in health and disease.

Authors:  Michael J Baker; Catherine S Palmer; Diana Stojanovski
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 6.  Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases.

Authors:  Epiphani C Simmons; Natalie E Scholpa; Rick G Schnellmann
Journal:  Exp Neurol       Date:  2020-04-11       Impact factor: 5.330

7.  Distribution and apoptotic function of outer membrane proteins depend on mitochondrial fusion.

Authors:  David Weaver; Verónica Eisner; Xingguo Liu; Péter Várnai; László Hunyady; Atan Gross; György Hajnóczky
Journal:  Mol Cell       Date:  2014-05-08       Impact factor: 17.970

8.  Mutation analysis of MFN2, GJB1, MPZ and PMP22 in Italian patients with axonal Charcot-Marie-Tooth disease.

Authors:  Giorgia Bergamin; Francesca Boaretto; Chiara Briani; Elena Pegoraro; Mario Cacciavillani; Andrea Martinuzzi; Maria Muglia; Andrea Vettori; Giovanni Vazza; Maria Luisa Mostacciuolo
Journal:  Neuromolecular Med       Date:  2014-05-13       Impact factor: 3.843

Review 9.  Mitochondrial fragmentation in neurodegeneration.

Authors:  Andrew B Knott; Guy Perkins; Robert Schwarzenbacher; Ella Bossy-Wetzel
Journal:  Nat Rev Neurosci       Date:  2008-07       Impact factor: 34.870

10.  Dominant GDAP1 founder mutation is a common cause of axonal Charcot-Marie-Tooth disease in Finland.

Authors:  Mari Auranen; Emil Ylikallio; Jussi Toppila; Mirja Somer; Sari Kiuru-Enari; Henna Tyynismaa
Journal:  Neurogenetics       Date:  2013-03-03       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.